HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0

CUSIP: 40637HAD1

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Debt / NOTE 0.250% 3/0
Market price (% of par)
97.14%
Total 13F principal
$676,406,024
Principal change
-$304,196,171
Total reported market value
$656,553,304
Number of holders
53
Value change
-$264,456,865
Number of buys
19
Number of sells
28

Quarterly Holders Quick Answers

What is CUSIP 40637HAD1?
CUSIP 40637HAD1 identifies 40637HAD1 - HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q4 2022

As of 31 Dec 2022, HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 was held by 53 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $676,406,024 in principal (par value) of the bond. The largest 10 bondholders included Voya Investment Management LLC, Davidson Kempner Capital Management LP, Invesco Ltd., CAMDEN ASSET MANAGEMENT L P /CA, AVIVA PLC, BlackRock Inc., CITIGROUP INC, STATE STREET CORP, ADVENT CAPITAL MANAGEMENT /DE/, and AMERIPRISE FINANCIAL INC. This page lists 53 institutional bondholders reporting positions for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.